Targeted nanoparticles for detecting and treating cancer

Drug Development Research

Volumn 67, Issue 1, 2006, Pages 70-93

  Sunderland, Christopher J ^a   Steiert, Matthias ^a   Talmadge, James E ^b   Derfus, Austin M ^c   Barry, Stephen E ^a  

^a Alnis BioSciences Inc   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cancer; Drug delivery; Magnetic; Nanoparticles; Targeting

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CASTOR OIL; CETUXIMAB; CISPLATIN; CONTRAST MEDIUM; CREMOPHOR; DENDRIMER; DOXORUBICIN; FERRIC OXIDE; GELDANAMYCIN; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; IRON OXIDE; LIGAND; LIPOSOME; MACROGOL; METHACRYLIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; NANOPARTICLE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PLATINUM; PLATINUM DERIVATIVE; POLYGLUTAMINE; TOSITUMOMAB I 131; TRASTUZUMAB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLLOID; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HEAT; HUMAN; HUMAN CELL; HYBRID; HYDROGEL; HYPERTHERMIC THERAPY; KAPOSI SARCOMA; MAGNETIC FIELD; MAGNETISM; MELANOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PARTICLE SIZE; SOLID TUMOR;

EID: 33646801567     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20069     Document Type: Article

References (118)

1. Allen TM. 2002. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2:750-763.
2. Allen TM, Martin FJ. 2004. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 31:5-15.
3. Alvarez Secord A, Jones EL, Hahn CA, Petros WP, Yu D, Havrilesky LJ, Soper JT, Berchuck A, Spasojevic I, Clarke-Pearson DL, Prosnitz LR, Dewhirst MW. 2005. Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. Int J Hypertherm 21:333-347.
4. Anderson RG, Kamen BA, Rothberg KG, Lacey SW. 1992. Potocytosis; sequestration and transport of small molecules by caveolae. Science 255:410-411.
5. Anufriyeva E, Birshtein T, Nekrasova T, Ptitsyn O, Sheveleva T 1968. J Polym Sci C 16:3519.
6. Arora A, Scholar EM. 2005. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther.
7. Bagshawe KD, Sharma SK, Begent RH. 2004. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther 4:1777-1789.
8. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. 2004. Noninvasive imaging of quantum dots in mice. Bioconjug Chem 15:79-86.
9. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M. 2005. Biodistribution and pharmacokinetics of the {alpha}v{beta}3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 46:1333-1341.
10. Bibby DC, Talmadge JE, Dalal MK, Kurz SG, Chytil KM, Barry SE, Shand DG, Steiert M. 2005. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int J Pharm 293:281-290.
11. Bjornerud A, Johansson LO, Briley-Saebo K, Ahlstrom HK. 2002. Assessment of T1 and T2* effects in vivo and ex vivo using iron oxide nanoparticles in steady state-dependence on blood volume and water exchange. Magn Reson Med 47:461-471.
12. Blagosklonny MV. 2002a. P53: an ubiquitous target of anticancer drugs. Int J Cancer 98:161-166.
13. Blagosklonny MV. 2002b. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 21:6249-6254.
14. Blagosklonny MV. 2003. Matching targets for selective cancer therapy. Drug Discov Today 8:1104-1107.
15. Brasch RC, Shames DM, Cohen FM, Kuwatsuru R, Neuder M, Mann JS, Vexler V, Muhler A, Rosenau W. 1994. Quantification of capillary permeability to macromolecular magnetic resonance imaging contrast media in experimental mammary adenocarcinomas. Invest Radiol 29(Suppl 2):S8-S11.
16. Cabral H, Nishiyama N, Okazaki S, Koyama H, Kataoka K. 2005. Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release 101:223-232.
17. Carpenter CP, Woodside MD, Kinkead ER, King JM, Sullivan LJ. 1971. Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization. Toxicol Appl Pharmacol 18:35-40.
18. Chabot GG. 1997. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245-259.
19. Chen FM, Wisner JR Jr, Omachi H, Renner IG, Taylor CR, Epstein AL. 1990. Localization of monoclonal antibody TNT-1 in experimental kidney infarction of the mouse. FASEB J 4:3033-3039.
20. Chen X, Park R, Shahinian AH, Bading JR, Conti PS. 2004. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31:11-19.
21. Cheng FM, Hansen EB, Taylor CR, Epstein AL. 1991. Diffusion and binding of monoclonal antibody TNT-1 in multicellular tumor spheroids. J Natl Cancer Inst 83:200-204.
22. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, Brasch RC. 1998. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Pediatr Radiol 28:67-78.
23. Daldrup-Link HE, Rydland J, Helbich TH, Bjornerud A, Turetschek K, Kvistad KA, Kaindl E, Link TM, Staudacher K, Shames D, Brasch RC, Haraldseth O, Rummeny EJ. 2003. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Radiology 229:885-892.
24. Damle NK. 2004. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin Biol Ther 4:1445-1452.
25. de Lussanet QG, Backes WH, Griffioen AW, van Engelshoven JM, Beets-Tan RG. 2003. Gadopentetate dimeglumine versus ultrasmall superparamagnetic iron oxide for dynamic contrast-enhanced MR imaging of tumor angiogenesis in human colon carcinoma in mice. Radiology 229:429-438.
26. Denny WA. 2004. Tumor-activated prodrugs: a new approach to cancer therapy. Cancer Invest 22:604-619.
27. Douwes F, Bogovi CJ, Douwes O, Migeod F, Grote C. 2004. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer. Int J Clin Oncol 9:85-91.
28. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743.
29. Duncan R. 2003. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347-360.
30. Fidler IJ, Talmadge JE. 1984. The evolution of biologic diversity in metastases. Transplant Proc 16:370-372.
31. Foley EA, Carter JD, Shan F, Guo T. 2005. Enhanced relaxation of nanoparticle-bound supercoiled DNA in X-ray radiation. Chem Commun:3192-3194.
32. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. 1990. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 31:1191-1198.
33. Fujita T, Nishikawa M, Ohtsubo Y, Ohno J, Takakura Y, Sezaki H, Hashida M. 1994. Control of in vivo fate of albumin derivatives utilizing combined chemical modification. J Drug Target 2:157-165.
34. Gabizon A, Martin F. 1997. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54(Suppl 4):15-21.
35. Gelderblom H, Verweij J, Nooter K, Sparreboom A. 2001. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-1598.
36. Ghobrial I, Witzig T. 2004. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology 18:623-640.
37. Gilchrest R, Medal R, Shorey W, Hanselman R, Parrott J, Taylor C. 1957. Selective inductive heating of lymph nodes. Ann Surg 146:596-606.
38. Gonzales M, Krishnan K. 2005. Synthesis of magnetoliposomes with monodisperse iron oxide nanocrystal cores for hyperthermia. J Magn Magn Mat 293:265-270.
39. Graff CP, Wittrup KD. 2003. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 63:1288-1296.
40. Greish K, Nagamitsu A, Fang J, Maeda H. 2005. Copoly(styrenemaleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjug Chem 16:230-236.
41. Grigorov MG. 2005. Global properties of biological networks. Drug Discov Today 10:365-372.
42. Han I, Kim OJ, Lee GY, Sung YK, Song R, Sohn YS. 2003. Enhanced antitumor activity [correction for activity] of trans(±)-1,2-diaminocyclo- hexaneglutamatoplatinum(II) formulated with stealth liposome. Bioorg Med Chem 11:5443-5447.
43. Harding J, Burtness B. 2005. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today 41:107-127.
44. Harris J, Zalipsky S, editors. 1997. Poly(ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society.
45. Hersel U, Dahmen C, Kessler H. 2003. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 24:4385-4415.
46. Hilger I, Hergt R, Kaiser WA. 2005. Use of magnetic nanoparticle heating in the treatment of breast cancer. IEE Proc Nanobiotechnol. 152:33-38.
47. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, Hazle JD, Halas NJ, West JL. 2003. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 100:13549-13554.
48. Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, Chang FH. 1999. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res 5:3645-3652.
49. Hynes NE, Lane HA. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354.
50. Izquierdo M. 2005. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 12:217-227.
51. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. 2005. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm 2:194-205.
52. Jordan A, Scholz R, Wust P, Fahling H, Felix R. 1999. Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magn Mat 201:413-419.
53. Karczmar GS, Fan X, Al-Hallaq HA, Zamora M, River JN, Rinker-Schaeffer C, Zaucha M, Tarlo K, Kellar K. 2000. Uptake of a superparamagnetic contrast agent imaged by MR with high spectral and spatial resolution. Magn Reson Med 43:633-639.
54. Kekre N, Griffin C, McNulty J, Pandey S. 2005. Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human lymphoma cells. Cancer Chemother Pharmacol 56:29-38.
55. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. 2000a. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 60:6950-6957.
56. Kong G, Braun RD, Dewhirst MW. 2000b. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 60:4440-4445.
57. Kong G, Braun RD, Dewhirst MW. 2001. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 61:3027-3032.
58. Kovar M, Mrkvan T, Strohalm J, Etrych T, Ulbrich K, Stastny M, Rihova B. 2003. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia. J Control Release 92:315-330.
59. Kusumoto T, Holden SA, Ara G, Teicher BA. 1995. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int J Hyperthermia 11:575-586.
60. Kwon GS. 2003. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst 20:357-403.
61. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. 2002. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 8:751-755.
62. Lavasanifar A, Samuel J, Kwon GS. 2002. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev 54:169-190.
63. Lee LS, Conover C, Shi C, Whitlow M, Filpula D. 1999. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug Chem 10:973-981.
64. Loo C, Lowery A, Halas N, West J, Drezek R. 2005. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett 5:709-711.
65. Low PS, Antony AC. 2004. Folate receptor-targeted drugs for cancer and inflammatory diseases, Adv Drug Deliv Rev 56:1055-1058.
66. Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM. 2005. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 23:3495-3501.
67. Maeda H. 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189-207.
68. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W, Duncan R. 2000. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 65:133-148.
69. Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA. 2004. Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res 64:1460-1467.
70. Mastrobattista E, Koning GA, Storm G. 1999. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 40:103-127.
71. Matsumura Y, Oda T, Maeda H. 1987. [General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics]. Can To Kagaku Ryoho 14:821-829.
72. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N. 2004. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91:1775-1781.
73. Mayers GL. 2006. Targeted Molecular brachytherapy. Drug Dev Res 67:94-106 (this issue).
74. Merkle EM, Boll DT, Boaz T, Duerk JL, Chung YC, Jacobs GH, Varnes ME, Lewin JS. 1999. MRI-guided radiofrequency thermal ablation of implanted VX2 liver tumors in a rabbit model: demonstration of feasibility at 02 T. Magn Reson Med 42:141-149.
75. Meyer DE, Shin BC, Kong GA, Dewhirst MW, Chilkoti A. 2001. Drug targeting using thermally responsive polymers and local hyperthermia. J Control Release 74:213-224.
76. Mineo C, Anderson RG. 2001. Potocytosis. Robert Feulgen Lecture. Histochem Cell Biol 116:109-118.
77. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB. 2000. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 56:318-325.
78. Muggia FM, Fojo T. 2004. Platinums: extending their therapeutic spectrum. J Chemother 16(Suppl 4):77-82.
79. Needham D, McIntosh TJ, Lasic DD. 1992. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta 1108:40-48.
80. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. 2000. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 60:1197-1201.
81. Nikolsky Y, Nikolskaya T, Bugrim A. 2005. Biological networks and analysis of experimental data in drug discovery. Drug Discov Today 10:653-662.
82. Oku N, Tokudome Y, Koike C, Nishikawa N, Mori H, Saiki I, Okada S. 1996. Liposomal Arg-Gly-Asp analogs effectively inhibit metastatic B16 melanoma colonization in murine lungs. Life Sci 58:2263-2270.
83. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. 2001. Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95-113.
84. Peyman A, Wehner V, Knolle J, Stilz HU, Breipohl G, Scheunemann KH, Carniato D, Ruxer JM, Gourvest JF, Gadek TR, Bodary S. 2000. RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements. Bioorg Med Chem Lett 10:179-182.
85. Pierschbacher MD, Ruoslahti E. 1984. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309:30-33.
86. Plank C, Scherer F, Schillinger U, Bergemann C, Anton M. 2003. Magnetofection: enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields. J Liposome Res 13:29-32.
87. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. 1997. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15:3185-3191.
88. Rihova B. 1996. Biocompatibility of biomaterials: hemocompatibility, immunocompatibility, and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv Drug Deliv Rev 21:157-176.
89. Rihova B, Etrych T, Pechar M, Jelinkova M, Stastny M, Hovorka O, Kovar M, Ulbrich K. 2001. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes. J Control Release 74:225-232.
90. Rivera E. 2003. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 8(Suppl 2):3-9.
91. Rose PG. 2005. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10:205-214.
92. Rose S. 1998. A proposal for a new direction to treat cancer. J Theor Biol 195:111-128.
93. Ruoslahti E, Pierschbacher MD. 1987. New perspectives in cell adhesion: RGD and integrins. Science 238:491-497.
94. Satchi R, Connors TA, Duncan R. 2001. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br J Cancer 85:1070-1076.
95. Satchi-Fainaro R, Hailu H, Davies JW, Summerford C, Duncan R. 2003. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjug Chem 14:797-804.
96. Schiffelers RM, Molema G, ten Hagen TL, Janssen AP, Schraa AJ, Kok RJ, Koning GA, Storm G. 2002. Ligand-targeted liposomes directed against pathological vasculature. J Liposome Res 12:129-135.
97. Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Storm G. 2003. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91:115-122.
98. Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, de Leij LF, Molema G. 2002. Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer 102:469-475.
99. Serin M, Erkal HS, Cakmak A. 1999. Radiation therapy, cisplatin and hyperthermia in combination in management of patients with carcinomas of the head and neck with N2 or N3 metastatic cervical lymph nodes. Radiother Oncol 50:103-106.
100. Seymour LW, Ulbrich K, Wedge SR, Hume IC, Strohalm J, Duncan R. 1991. N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. Br J Cancer 63:859-866.
101. Shames DM, Kuwatsuru R, Vexler V, Muhler A, Brasch RC. 1993. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 29:616-622.
102. Shoji Y, Nakashima H. 2004. Current status of delivery systems to improve target efficacy of oligonucleotides. Curr Pharm Des 10:785-796.
103. Smedsrod B. 2004. Clearance function of scavenger endothelial cells. Comp Hepatol 3(Suppl 1):S22.
104. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. 2005. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105:855-861.
105. Talmadge JE, Benedict K, Madsen J, Fidler IJ. 1984. Development of biological diversity and susceptibility to chemotherapy in murine cancer metastases. Cancer Res 44:3801-3805.
106. Tucker GC. 2003. Alpha v integrin inhibitors and cancer therapy. Curr Opin Invest Drugs 4:722-731.
107. Turetschek K, Huber S, Floyd E, Helbich T, Roberts TP, Shames DM, Tarlo KS, Wendland MF, Brasch RC. 2001. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology 218:562-569.
108. Uchida K, Otsuka H, Kaneko M, Kataoka K, Nagasaki Y. 2005. A reactive poly(ethylene glycol) layer to achieve specific surface plasmon resonance sensing with a high S/N ratio: the substantial role of a short underbrushed PEG layer in minimizing nonspecific adsorption. Anal Chem 77:1075-1080.
109. Ulbrich K, Etrych T, Chytil P, Jelinkova M, Rihova B. 2004. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J Drug Target 12:477-489.
110. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJ. 2001. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97:3197-3204.
111. Vieth M, Sutherland JJ, Robertson DH, Campbell RM. 2005. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today 10:839-846.
112. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. 2004. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med 51:1153-1162.
113. Weidner N, Semple JP, Welch WR, Folkman J. 1991. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8.
114. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr, Kamen BA. 1992a. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52:3396-3401.
115. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA. 1992b. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 52:6708-6711.
116. Westermann AM, Grosen EA, Katschinski DM, Jager D, Rietbroek R, Schink JC, Tiggelaar CL, Jager E, Zum Vorde sive Vording P, Neuman A, Knuth A, Van Dijk JD, Wiedemann GJ, Robins HI. 2001. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur J Cancer 37:1111-1117.
117. Westermann AM, Jones EL, Schem BC, van der Steen-Banasik EM, Koper P, Mella O, Uitterhoeve AL, de Wit R, van der Velden J, Burger C, van der Wilt CL, Dahl O, Prosnitz LR, van der Zee J. 2005. First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma. Cancer 104:763-770.
118. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM. 2003. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(v)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 63:5838-5843.